VIBLIOME
Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.
VIBLIOME
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Bozeman, Montana, United States
Country:
United States
Website Url:
http://www.vibliome.com
Total Employee:
11+
Status:
Active
Contact:
(406) 595-3483
Total Funding:
46 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Google Tag Manager Google Analytics Content Delivery Network SSL By Default Global Site Tag Google Universal Analytics
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
ValenzaBio
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases.
Current Employees Featured
Founder
Investors List
Deerfield
Deerfield investment in Series A - Vibliome
Official Site Inspections
http://www.vibliome.com Semrush global rank: 15.74 M Semrush visits lastest month: 1
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 13.248.243.5
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Vibliome"
Vibliome - Crunchbase Company Profile & Funding
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications. View contacts for Vibliome to access new leads and connect with decision-makers.See details»
Vibliome Company Profile - Office Locations, Competitors ... - Craft
Vibliome Therapeutics is a company developing a family of therapeutics for the treatment of cancer, contraception, and other indications. It provides a non-hormonal male birth control pill …See details»
Vibliome Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Vibliome Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Vibliome Therapeutics, LLC | LinkedIn
Our mission to develop new therapeutic options for patients is backed by Deerfield Management in New York, a private equity firm committed to improving healthcare through investment,...See details»
Vibliome Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Vibliome Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Vibliome Therapeutics - Overview, News & Similar companies
Feb 23, 2022 · View Vibliome Therapeutics (www.vibliome.com) location in Montana, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Vibliome - VentureRadar
Website: https://vibliome.com/ Vibliome Therapeutics, LLC, has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique profiles …See details»
Vibliome Therapeutics, LLC Asset Profile | Preqin
Based in Massachusetts, US, and founded in 2017 by Gary Flynn, Vibliome Therapeutics, LLC, is a research-based organization involved in the study of small-molecule Type II Kinase inhibitors …See details»
Vibliome - Funding, Financials, Valuation & Investors - Crunchbase
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.See details»
Vibliome - Crunchbase
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.See details»
Robert Goodwin - CEO at Vibliome Therapeutics | The Org
Dr. Robert Goodwin is the current CEO at Vibliome Therapeutics. Robert has over 25 years of experience in the pharmaceutical industry. Prior to joining Vibliome, they served as Vice …See details»
Vibliome Therapeutics Spins Off New Company, Raises Additional …
Feb 24, 2022 · Beartooth Therapeutics is a new company co-founded by Vibliome and Deerfield Management, which plans to finalize development candidates and advance the programs into …See details»
Vibliome Therapeutics LLC - Drug pipelines, Patents, Clinical trials ...
Explore Vibliome Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 1 news, and 2 literature, Disease Domain:Neoplasms, Immune System Diseases, Technology …See details»
Vibliome Therapeutics - Biotech Careers
Vibliome develops small molecule kinase inhibitor drug candidates for treating cancer, immune diseases and fibrosis. Business Areas: Small Molecules, Protein Kinase.See details»
Male Contraception Initiative Awards $500K Research Grant to …
Nov 2, 2017 · DURHAM, N.C.-- ( BUSINESS WIRE )--Today the Male Contraception Initiative (MCI), a private non-profit foundation, announced the award of a $500,000 grant to Vibliome …See details»
Vibliome - Contacts, Employees, Board Members, Advisors & Alumni
Vibliome has 3 current employee profiles, including Founder Gary Flynn. Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.See details»
Vibliome Therapeutics and AssayQuant Technologies, Inc. Establish ...
Aug 2, 2022 · Vibliome has developed a novel, highly annotated small molecule Type II kinase inhibitor library and a systematic approach for the generation of drug candidates with unique …See details»
Vibliome Therapeutics - Male Contraceptive Initiative
Vibliome was incorporated in 2017 to establish proof of concept in humans for a new family of highly selective small molecule kinase inhibitors offering both reversible and irreversible …See details»
Series A - Vibliome - 2022-02-24 - Crunchbase
Feb 24, 2022 · Vibliome raised $38000000 on 2022-02-24 in Series A. Deerfield Deerfield is an investment firm that transforms healthcare through information, investment, and philanthropy.See details»
Vibliome Therapeutics Closes First Tranche of Its $16 million Series …
Deerfield Management was the sole investor in the Series A financing round and will be providing operational support. Vibliome has discovered a new systematic approach for the development …See details»